Trial Profile

A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

15 Apr 2025 According to a Eyestem media release, the company will be presenting its data at the ARVO 2025 Annual Meeting as well as the 10th Retinal Cell and Gene Therapy Innovation Summit in early May.
15 Apr 2025 Results presented in the Eyestem media release.
06 Jan 2025 According to a Eyestem media release, the company Completing the first three patient injections of Eyecyte-RPE™ represent a critical milestone for our quest to find a cure for Dry AMD.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com